Shares of Mednax Inc. (NYSE:MD) have been assigned a consensus rating of “Hold” from the eleven analysts that are currently covering the firm. Six equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $73.75.

Several analysts have issued reports on MD shares. Mizuho cut Mednax from a “buy” rating to a “neutral” rating and dropped their target price for the company from $69.00 to $64.00 in a research report on Wednesday, November 9th. Citigroup Inc. lowered their price objective on Mednax from $76.00 to $72.00 and set a “neutral” rating for the company in a research report on Wednesday, August 17th. Zacks Investment Research cut Mednax from a “hold” rating to a “sell” rating in a research report on Wednesday, October 19th. Jefferies Group lowered their price objective on Mednax from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Friday, August 26th. Finally, Raymond James Financial Inc. cut Mednax from an “outperform” rating to a “market perform” rating in a research report on Thursday, October 27th.

Shares of Mednax (NYSE:MD) traded down 0.08% on Wednesday, reaching $65.96. 151,467 shares of the company traded hands. The company has a market capitalization of $6.11 billion, a PE ratio of 18.12 and a beta of 0.62. Mednax has a 52-week low of $59.36 and a 52-week high of $76.96. The firm has a 50-day moving average of $63.96 and a 200-day moving average of $67.35.

Mednax (NYSE:MD) last announced its earnings results on Thursday, October 27th. The company reported $1.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.11 by $0.02. The company had revenue of $828 million for the quarter, compared to the consensus estimate of $821.18 million. Mednax had a net margin of 10.97% and a return on equity of 14.47%. The firm’s revenue was up 14.6% compared to the same quarter last year. During the same period last year, the business posted $1.10 EPS. On average, equities research analysts forecast that Mednax will post $4.04 earnings per share for the current fiscal year.

In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,500 shares of Mednax stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $65.01, for a total transaction of $97,515.00. Following the completion of the transaction, the director now owns 12,755 shares in the company, valued at approximately $829,202.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.40% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in MD. Legal & General Group Plc raised its position in Mednax by 17.4% in the first quarter. Legal & General Group Plc now owns 63,195 shares of the company’s stock worth $4,085,000 after buying an additional 9,350 shares during the last quarter. Arizona State Retirement System raised its position in Mednax by 5.8% in the first quarter. Arizona State Retirement System now owns 51,467 shares of the company’s stock worth $3,326,000 after buying an additional 2,800 shares during the last quarter. Squarepoint Ops LLC raised its position in Mednax by 21.4% in the first quarter. Squarepoint Ops LLC now owns 9,326 shares of the company’s stock worth $603,000 after buying an additional 1,641 shares during the last quarter. First Republic Investment Management Inc. raised its position in Mednax by 107.9% in the first quarter. First Republic Investment Management Inc. now owns 8,354 shares of the company’s stock worth $540,000 after buying an additional 4,336 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its position in Mednax by 1,821.7% in the second quarter. BNP Paribas Arbitrage SA now owns 39,279 shares of the company’s stock worth $2,845,000 after buying an additional 37,235 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Mednax Inc. (MD) Given Average Recommendation of “Hold” by Analysts” was originally posted by Financial Market News and is owned by of Financial Market News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of United States & international copyright laws. The legal version of this article can be accessed at http://www.financial-market-news.com/mednax-inc-md-given-average-recommendation-of-hold-by-analysts/1210872/.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

5 Day Chart for NYSE:MD

Receive News & Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.